Expert Interview
A Third Look: Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderate to severe Crohn's disease
Ticker(s): JNJ, ABBV, LLYInstitution: NYU
- Assistant Professor of Medicine in the Division of Gastroenterology at NYU Grossman School of Medicine & gastroenterologist at the IBD Center at NYU Langone Health.
- Manages 350 unique patients with Crohn's disease annually.
- Extremely familiar with study data and was PI on trials from Vedanta and Gilead in UC.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
